Recent advances in antibody Fc engineering—such as enhancing FcγR binding affinity—have been employed to improve ADCC, and in this context, modulating FCGR2A expression or function may provide a novel entry point to boost ICI responsiveness in HCC (56). The gene discussed is FCGR2A; the disease is hepatocellular carcinoma.